This is the authors' abstract. We don't add key points for this paper.
SARS-CoV-2 remains a global threat, despite the rapid deployment but limited coverage of multiple vaccines. Alternative vaccine strategies that have favorable manufacturing timelines, greater ease of distribution, and improved coverage may offer significant public health benefits, especially in resource-limited settings. Live oral vaccines have the potential to address some of these limitations; however, no studies have yet been conducted to assess the immunogenicity and protective efficacy of a live oral vaccine against SARS-CoV-2. Here, we report that oral administration of live SARS-CoV-2 in nonhuman primates may offer prophylactic benefits, but the formulation and route of administration will require further optimization.
Answers are grounded in this paper and cite their sources.
No takes yet. Share an insight, caveat, or question.
Yu et al. (2021) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: